Saffron (Crocus sativus L.) and major depressive disorder: a meta-analysis of randomized clinical trials
Key Finding
Saffron (30mg daily) was as effective as fluoxetine and imipramine for depression while producing fewer side effects.
Plain-English Summary
This meta-analysis examined 5 randomized clinical trials comparing saffron to placebo and to conventional antidepressants (fluoxetine, imipramine) for major depressive disorder. Doses were typically 30mg of saffron extract daily.
Saffron was significantly more effective than placebo for reducing depression symptoms, with large effect sizes. Remarkably, saffron was found to be equivalent in efficacy to fluoxetine and imipramine, two established antidepressants, while producing fewer side effects.
Saffron's active compounds (crocin and safranal) modulate serotonin metabolism, reduce neuroinflammation, and have antioxidant effects in the brain. The herb has been used in traditional Persian medicine for mood support for centuries. The 30mg daily dose is well-tolerated and cost-effective compared to pharmaceutical alternatives.